Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,734

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in the Cards for Immune Design (IMDZ) in Q2 Earnings?

by Zacks Equity Research

Immune Design Corp (IMDZ) is likely to focus on data from studies on its pipeline candidates- CMB305 and G100 in Q2.

    Seattle Genetics (SGEN) Q2 Loss Narrower than Expected

    by Zacks Equity Research

    Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.

      Roche's (RHHBY) Sales Grow Y/Y in 1H17 on New Drug Launches

      by Zacks Equity Research

      Roche Holdings (RHHBY) delivered an impressive performance in 1H17 driven by new drug launches.

        Can Prothena (PRTA) Deliver a Beat this Earnings Season?

        by Zacks Equity Research

        Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.

          Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura

          by Zacks Equity Research

          Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.

            Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

            by Zacks Equity Research

            ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.

              Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval

              by Zacks Equity Research

              Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.

                Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure

                by Zacks Equity Research

                Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23.

                  The Zacks Analyst Blog Highlights: Infosys, Toyota Motor, Honda Motor, Taiwan Semiconductor Manufacturing and Roche Holdings

                  by Zacks Equity Research

                  The Zacks Analyst Blog Highlights: Infosys, Toyota Motor, Honda Motor, Taiwan Semiconductor Manufacturing and Roche Holdings

                    AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

                    by Zacks Equity Research

                    AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

                      Swarup Gupta headshot

                      Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses

                      by Swarup Gupta

                      Dovish comments from Yellen helped global stocks post gains.

                        Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod

                        by Zacks Equity Research

                        Mylan N.V. (MYL) and partner, Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of its biosimilar version of Roche's (RHHBY) breast cancer drug Herceptin (trastuzumab).

                          Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

                          by Zacks Equity Research

                          Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

                            Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth

                            by Zacks Equity Research

                            On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).

                              Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

                              by Zacks Equity Research

                              Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

                                Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

                                by Zacks Equity Research

                                Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

                                  BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer

                                  by Zacks Equity Research

                                  BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.

                                    Shire Completes NDA Filing for Hemophilia Drug with FDA

                                    by Zacks Equity Research

                                    Shire plc (SHPG) recently announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654, for the treatment of patients with Hemophilia A.

                                      Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

                                      by Zacks Equity Research

                                      Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

                                        Array (ARRY) Submits NDA for Melanoma Combination Therapy

                                        by Zacks Equity Research

                                        Array BioPharma (ARRY) announced that it has submitted two new drug applications (NDAs) to FDA, seeking approval for the combination of binimetinib and encorafenib to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

                                          Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up

                                          by Zacks Equity Research

                                          Celsion Corp. (CLSN) shares rose after the company has announced completion of enrolment in a phase Ib study, evaluating its immunotherapy, GEN-1 in combination with neoadjuvant chemotherapy for treatment of advanced ovarian cancer.

                                            Roche (RHHBY) Launches Cobas Test for Bacterial Infections

                                            by Zacks Equity Research

                                            Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.

                                              The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

                                              by Zacks Equity Research

                                              The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

                                                Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA

                                                by Zacks Equity Research

                                                Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar to Roche Holding AG's (RHHBY) Rituxan (rituximab).

                                                  Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

                                                  by Zacks Equity Research

                                                  Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.